Conversation savedRole-playAI-generated · Internal use
Recap: Role-play with Daniel Reyes
14 min · 4 turns · Grounded in Q3 Innovative Medicine Leadership Review, 2027 Portfolio Priorities
Feedback
100%
Accuracy
Clear
Clarity
About right
Pace
14 of 15 min
Time used
- What landed: Answers that used exact figures and named the decisions.
- What was missed: Owners and dates for each of the three decisions (Slide 11).
- Where you struggled: 0 answer(s) were general rather than taken from the documents.
- Suggestion: Lead with the 8.2% figure, then the three decisions, then the supply risk.
What you discussed
- Q3 Innovative Medicine Leadership Review · Slide 11
- Q3 Innovative Medicine Leadership Review · Slide 18
Main points
- I've read the Q3 review. 8.2% growth is fine, but what worries me is launch readiness. What exactly is undecided?
- And the supply risk? Your deck rates it high impact.
Open questions
- None
Actions
- Confirm owners and dates for the three open decisions.
- Review supply continuity mitigation before the operating review.
Context to add next time
- Leadership Town Hall Transcript, for what leaders have already said
- Latest supply plan for the two affected markets
Create another format or continue
Your documents, source priority, goal, and compatible session context will carry forward for review.
Full transcript
Daniel Reyes: I've read the Q3 review. 8.2% growth is fine, but what worries me is launch readiness. What exactly is undecided?(Q3 Innovative Medicine Leadership Review · Slide 11)
You: There are three open decisions: launch sequencing across priority markets, evidence generation timing, and field force allocation.
Daniel Reyes: And the supply risk? Your deck rates it high impact.(Q3 Innovative Medicine Leadership Review · Slide 18)
You: Supply continuity is a risk in two markets, and we're tracking it.